Why Is ImmunityBio, Inc. Common Stock (IBRX) Stock Down 28.0% Today?

ImmunityBio, Inc. Common Stock (IBRX) collapsed 28.0% today, falling from yesterday's $9.40 close to $6.885 as of mid-afternoon trading on March 24, 2026. The biotech stock traded 21.6 million shares—marking elevated activity but still 0.8x the typical daily volume—wiping $2.5 billion in market value as the selloff accelerated. After climbing 11% on March 23 following a positive bladder cancer treatment milestone, IBRX gave back all gains and more, leaving investors asking: why is ImmunityBio stock down so sharply today?

What's Driving IBRX Stock Down Today

The 28% decline appears rooted in profit-taking rather than a specific negative catalyst. IBRX had surged 11% on March 23 after the American Urological Association issued updated guidelines favoring the use of Anktiva (formerly known as bacillus Calmette-Guérin, or BCG alternative) for bladder cancer patients—a potential tailwind for ImmunityBio's commercial strategy. That rally capped a multi-day run that began March 13 when the stock jumped on positive phase trial results.

Biotech stocks often experience sharp reversals after sustained rallies, particularly when a catalyst has been widely anticipated and the company lacks major near-term newsflow to sustain momentum. The 0.8x volume ratio suggests institutional sellers may have exited positions at higher prices, though retail capitulation didn't trigger the kind of panic volume (2x-3x average) that signals a major fundamental break.

With no press release or SEC filing disclosed during today's session, this appears to be technical rather than fundamental—a classic "buy the rumor, sell the news" scenario where enthusiasm about the AUA guideline has been priced in and traders are locking profits ahead of any company-specific announcements. The biotech sector has also faced broader pressure, with uncertainty around healthcare policy and biotech valuations creating a risk-off environment for smaller-cap oncology plays.

IBRX Stock Key Levels to Watch

IBRX broke below the $8.00 level decisively, which had acted as support during the March 17-23 rally. The stock is now trading at $6.885, testing the $6.50 area that marked the day's low. The 50-day moving average sits around $7.40, and the 200-day sits near $6.20, meaning today's collapse brought IBRX to test its intermediate moving average support.

The 52-week range spans $4.67 (low, set in late 2025) to $12.18 (high, set in February 2026), placing today's price 47% above the yearly lows but 43% below the recent peak. If selling accelerates further, the next major support level would be the $6.00 psychological floor and the 200-day moving average confluence near $6.20. A close below that would signal a deeper correction and potentially trigger stop-loss orders.

On the upside, a recovery back above $8.00 would be required to re-establish the short-term trend, with $9.00 (yesterday's spike high) serving as the first resistance. The elevated volume today—while not panic-level—suggests institutional involvement; a quiet recovery on low volume would indicate weak conviction among buyers.

What Analysts Say About IBRX Stock

Analyst sentiment on ImmunityBio remains cautiously optimistic despite today's crash, with the consensus centered on the commercial potential of Anktiva and the breadth of the pipeline. The updated AUA guidelines published March 17 explicitly recommended Anktiva for certain bladder cancer cohorts, removing uncertainty around whether oncologists would adopt the therapy.

The bull case rests on Anktiva adoption accelerating throughout 2026 and 2027, with peak annual sales potentially reaching $400M-$600M, and the pipeline producing additional shots on goal. The bear case points to biotech valuation compression, the execution risk of new cancer therapies, and potential pricing pressure in the oncology market. Analyst price targets have ranged from $8.00 on the conservative end to $14.00+ on the bull side pre-crash, implying 16%-103% upside from today's $6.885 close.

The selloff has compressed the risk-reward profile considerably. At $6.885, a recovery to the $10.00-$11.00 range seen in recent weeks looks more achievable near-term, but conviction has deteriorated. Any near-term analyst downgrades or guidance cuts would likely accelerate the decline further; conversely, a company announcement of clinical progress or commercial traction could reignite the rally.

What's Next for ImmunityBio Stock

The immediate catalyst for IBRX will be company commentary on Anktiva market penetration and commercial ramp-up. ImmunityBio typically provides quarterly updates on prescriber adoption and patient enrollment metrics. If management signals strong initial uptake of Anktiva following the AUA guideline endorsement, it could support a recovery. Conversely, if early sales data disappoint, today's decline could accelerate.

Bull case: Anktiva adoption accelerates to 8,000+ prescriptions by Q2 2026, management raises full-year revenue guidance, and the stock rallies back to $10.00-$11.00 within 4-6 weeks. The updated guidelines provide a multi-year tailwind for bladder cancer indications.

Bear case: Adoption underperforms expectations due to physician hesitancy or reimbursement barriers, competitive pressures mount from other immunotherapies, and IBRX guides lower, sending the stock toward $5.50-$6.00 support. Biotech valuations remain under pressure through Q2.

Key date to monitor: ImmunityBio's next earnings call, likely scheduled for late April or May 2026, when management will provide detailed Anktiva commercial metrics. Investors should also watch for any FDA action letters or clinical trial updates on the broader pipeline—particularly phase 2/3 programs in lung and colorectal cancer.

Frequently Asked Questions

Why is IBRX stock down today?

IBRX plunged 28% on March 24, 2026, after rallying 11% the prior day following positive bladder cancer guideline news from the American Urological Association. The selloff appears driven by profit-taking and a lack of new catalysts to sustain momentum, not a fundamental negative catalyst. Biotech stocks often reverse sharply after multi-day rallies, particularly when the news has been widely anticipated.

Is IBRX stock a buy at $6.885?

This depends on your risk tolerance and time horizon. Analyst consensus is cautiously bullish on the Anktiva commercial opportunity, with price targets ranging from $8.00 to $14.00, implying upside from current levels. However, biotech stocks are speculative, and execution risk is high. Understanding chart support and resistance levels can help determine appropriate entry and exit points. Any investment decision should align with your portfolio strategy.

What is IBRX's analyst price target?

Analyst price targets on ImmunityBio range from $8.00 (conservative case) to $14.00+ (bull case), with an estimated consensus around $10.50-$11.00 prior to today's crash. At $6.885, this implies 16%-55% upside from current levels based on pre-crash estimates. However, today's volatile action may prompt analyst revisions in coming days.

What is ImmunityBio's market cap?

IBRX's market capitalization fell to approximately $9.7 billion today, down from $13.2 billion at yesterday's close. The company has roughly 1.4 billion shares outstanding, making it a mid-cap biotech player. For context on market cap and how it affects stock valuation, see our complete guide to market capitalization.

When does IBRX report earnings next?

ImmunityBio typically reports quarterly results in late April or May. The next earnings call is expected to provide commercial update on Anktiva adoption rates and guidance for full-year 2026 revenue and cash burn. This will be the key moment for management to address today's selloff and confirm the thesis around bladder cancer market penetration.

The Bottom Line

IBRX's 28% crash on March 24 is a sharp reversal from momentum, but it reflects biotech volatility more than a fundamental break. The updated AUA guideline for Anktiva remains favorable for the company's commercial prospects, and the pipeline still represents optionality. However, today's profit-taking suggests that a near-term catalyst—either positive commercial data or a new clinical milestone—will be needed to reignite the rally.

At $6.885, IBRX is back to where it traded before the March 17 guideline announcement, erasing the benefit of what management would likely call "a key validation." The stock remains 47% above its 52-week lows, and if Anktiva adoption accelerates as hoped, the current price could look attractive in 6-12 months. But near-term, traders should watch for support holds at $6.50 and revenue guidance confirmation. For more market analysis and breaking stock news, stay tuned to Ticker Daily.